These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 35149096)
1. Carboxymethyl chitosan modified lipid nanoformulations as a highly efficacious and biocompatible oral anti-leishmanial drug carrier system. Singh A; Yadagiri G; Negi M; Kushwaha AK; Singh OP; Sundar S; Mudavath SL Int J Biol Macromol; 2022 Apr; 204():373-385. PubMed ID: 35149096 [TBL] [Abstract][Full Text] [Related]
2. Enhancing Safety and Efficacy by Altering the Toxic Aggregated State of Amphotericin B in Lipidic Nanoformulations. Das S; Devarajan PV Mol Pharm; 2020 Jun; 17(6):2186-2195. PubMed ID: 32324420 [TBL] [Abstract][Full Text] [Related]
3. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Parvez S; Yadagiri G; Gedda MR; Singh A; Singh OP; Verma A; Sundar S; Mudavath SL Sci Rep; 2020 Jul; 10(1):12243. PubMed ID: 32699361 [TBL] [Abstract][Full Text] [Related]
4. Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani. Tripathi P; Jaiswal AK; Dube A; Mishra PR Int J Biol Macromol; 2017 Dec; 105(Pt 1):625-637. PubMed ID: 28716750 [TBL] [Abstract][Full Text] [Related]
6. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis. Khatik R; Dwivedi P; Khare P; Kansal S; Dube A; Mishra PR; Dwivedi AK Expert Opin Drug Deliv; 2014 May; 11(5):633-46. PubMed ID: 24606222 [TBL] [Abstract][Full Text] [Related]
7. Improvising anti-leishmanial activity of amphotericin B and paromomycin using co-delivery in d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) tailored nano-lipid carrier system. Parvez S; Yadagiri G; Singh A; Karole A; Singh OP; Sundar S; Mudavath SL Chem Phys Lipids; 2020 Sep; 231():104946. PubMed ID: 32621810 [TBL] [Abstract][Full Text] [Related]
8. Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity. Parvez S; Yadagiri G; Karole A; Singh OP; Verma A; Sundar S; Mudavath SL Front Cell Infect Microbiol; 2020; 10():570573. PubMed ID: 33178626 [TBL] [Abstract][Full Text] [Related]
9. Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Zadeh Mehrizi T; Khamesipour A; Shafiee Ardestani M; Ebrahimi Shahmabadi H; Haji Molla Hoseini M; Mosaffa N; Ramezani A Int J Nanomedicine; 2019; 14():7593-7607. PubMed ID: 31802863 [TBL] [Abstract][Full Text] [Related]
18. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy. Fu T; Yi J; Lv S; Zhang B J Liposome Res; 2017 Sep; 27(3):228-233. PubMed ID: 27601177 [TBL] [Abstract][Full Text] [Related]
19. Self-aggregated nanoparticles based on amphiphilic poly(lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B. Zhou W; Wang Y; Jian J; Song S Int J Nanomedicine; 2013; 8():3715-28. PubMed ID: 24106427 [TBL] [Abstract][Full Text] [Related]